Genki Tohnai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Genki Tohnai has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
C. Frank Bennett
IONIS Pharmaceuticals, Carlsbad, USA
1 shared publicationKazunari Onodera
Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan
1 shared publicationKenji Sakakibara
Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan
1 shared publicationKentaro Maeda
Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan
1 shared publication- Kentaro Sahashi
Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan
1 shared publication - Madoka Iida
Department of Neurology Nagoya University Graduate School of Medicine Nagoya Japan
1 shared publication
Latest Publications
- Open Access
- 27 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 2412
Restoring early postnatal synaptic dysregulation rescues motor neuron degeneration in a mouse model of Spinal and Bulbar Muscular Atrophy
Spinal and bulbar muscular atrophy (SBMA) is an adult-onset neurodegenerative disorder caused by expansion of a polyglutamine tract in the androgen receptor (AR). Here, we show that polyglutamine-expanded AR accumulates in the nucleus of motor neurons and induces aberrant upregulation of glutamatergic synaptic genes through dysfunction of the master transcriptional repressor REST during early postnatal development in a mouse model of SBMA (AR-97Q mice). Reducing mutant AR or restoring REST function using antisense oligonucleotides during the neonatal period attenuated the upregulation of glutamatergic synaptic genes and ameliorated the disease phenotype and histopathology in AR-97Q mice. Furthermore, we observed increased calcium activity in induced pluripotent stem cell-derived motor neurons from SBMA patients compared to those from healthy controls, reflecting neuronal hyperexcitability. Late-onset neurodegeneration in SBMA is attributable to early synaptic defects and the resulting hyperexcitability of motor neurons, which may represent therapeutic targets.
- 27 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 2412
Open AccessRestoring early postnatal synaptic dysregulation rescues motor neuron degeneration in a mouse model of Spinal and Bulbar Muscular Atrophy
Spinal and bulbar muscular atrophy (SBMA) is an adult-onset neurodegenerative disorder caused by expansion of a polyglutamine tract in the androgen receptor (AR). Here, we show that polyglutamine-expanded AR accumulates in the nucleus of motor neurons and induces aberrant upregulation of glutamatergic synaptic genes through dysfunction of the master transcriptional repressor REST during early postnatal development in a mouse model of SBMA (AR-97Q mice). Reducing mutant AR or restoring REST function using antisense oligonucleotides during the neonatal period attenuated the upregulation of glutamatergic synaptic genes and ameliorated the disease phenotype and histopathology in AR-97Q mice. Furthermore, we observed increased calcium activity in induced pluripotent stem cell-derived motor neurons from SBMA patients compared to those from healthy controls, reflecting neuronal hyperexcitability. Late-onset neurodegeneration in SBMA is attributable to early synaptic defects and the resulting hyperexcitability of motor neurons, which may represent therapeutic targets.